Thursday, August 20, 2026. 12 PM-1:30 PM ET
Hear from an expert in HER2 IHC whose work has contributed to current scoring guidelines.
Webinar presenter Josef Ruschoff, MD, PhD, Former Chief Medical Officer and Co-Founder of Targos, Senior Consultant of Discovery Life Sciences, Kassel, Germany.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
To be rescheduled to a future date
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2026—QuidelOrtho has completed the acquisition of Lex Diagnostics for about $100 million in cash. The acquisition follows the FDA 510(k) clearance and CLIA waiver of the Lex Velo molecular diagnostics platform in February.
July 2026—CareDx has entered into a definitive agreement to acquire Naveris for $160 million up front plus up to $100 million in additional payments tied to revenue milestones. Naveris is a precision oncology diagnostics company with a Medicare-reimbursed, blood‑based monitoring test for cancers caused by viral infections.
July 2026—Labcorp announced that ColoSense, an FDA-approved, at-home test for colorectal cancer screening, is now available for adults ages 45 to 85 who are at average risk for developing CRC. The test uses RNA-based technology to detect biomarkers associated with colorectal cancer and advanced adenomas.
July 2026—Labcorp and Children’s Hospital of Philadelphia are collaborating to advance the discovery, development, and availability of specialized pediatric diagnostics. CHOP and Labcorp will create a joint pediatric diagnostics innovation pipeline in which the organizations will identify, develop, and expand new tests and technologies, with the aim of streamlining the path from discovery to national availability.
July 2026—Grifols launched at the International Society of Blood Transfusion Congress (Kuala Lumpur, Malaysia, June 20–24) the Evanzys IH, a modular, fully automated, track-enabled system designed to streamline operations and reduce manual intervention in immunohematology sample processing.
June 2026—Qiagen has released the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR panel.
June 2026—Anchor Molecular launched its BCR-ABL1 control panels designed to support laboratories in monitoring the performance of the quantitative detection of BCR-ABL1 translocation mRNA transcripts.
June 2026—Bruker announced at ESCMID Global 2026 (Munich, April 17–21) portfolio enhancements to its MALDI Biotyper workflow. The proprietary MBT Easy T kit, available for research use only or CE-IVD marked under the EU IVDR, is designed to simplify and standardize sample transfer steps to MALDI target plates. It includes ready-to-use reagents and applicators, supporting up to 2,000 samples, and features room-temperature storage.
June 2026—Artera has been granted the CE mark under the European Union in vitro diagnostic regulation for its ArteraAI Prostate Biopsy and ArteraAI Breast Cancer assays.
June 2026—Streck launched CD-Chex Daily, a ready-to-use quality control for flow cytometry laboratories. It provides coverage across 51 assayed, research-use-only markers in a single vial, with markers spanning surface, intracellular, and leukocyte scatter populations, including CD200, TRBC1, cMPO, CD27, CD36, CD81, cCD79a, CD79b, cKappa, cLambda, and others.
